European Commission approves mAbxience's bevacizumab (to be commercialised as Alymsys and Oyavas) for treatment of certain types of cancer

This was found to be highly similar to Avastin and is intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

Source:

Biospace Inc.